GB2071671A - Polypeptide production - Google Patents
Polypeptide production Download PDFInfo
- Publication number
- GB2071671A GB2071671A GB8108136A GB8108136A GB2071671A GB 2071671 A GB2071671 A GB 2071671A GB 8108136 A GB8108136 A GB 8108136A GB 8108136 A GB8108136 A GB 8108136A GB 2071671 A GB2071671 A GB 2071671A
- Authority
- GB
- United Kingdom
- Prior art keywords
- gene
- fused
- polypeptide
- region
- coding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 84
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 84
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 84
- 238000004519 manufacturing process Methods 0.000 title description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 151
- 238000000034 method Methods 0.000 claims abstract description 31
- 244000005700 microbiome Species 0.000 claims abstract description 19
- 238000013519 translation Methods 0.000 claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 9
- 238000010367 cloning Methods 0.000 claims abstract description 7
- 239000012634 fragment Substances 0.000 claims description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 101150079483 colt gene Proteins 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 15
- 230000004927 fusion Effects 0.000 description 11
- 230000014616 translation Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 101100370749 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) trpC1 gene Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical class ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 238000003168 reconstitution method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 101150016309 trpC gene Proteins 0.000 description 1
- 101150100816 trpD gene Proteins 0.000 description 1
- 101150079930 trpGD gene Proteins 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Abstract
Compositions and methods featuring, in one aspect, a method of providing a fused gene having a promoter located an optimal distance from the translation start site, the method including providing a fused gene having a region of a gene coding for a eukaryotic or prokaryotic polypeptide fused to a region of a gene coding for an assayable polypeptide, inserting a portable promotor at varying distances in front of the translation start site, cloning the fused genes into microorganisms, selecting those producing the greatest amount of assayable polypeptide, and reconstituting the gene for the eukaryotic or prokaryotic protein.
Description
SPECIFICATION
Polypeptide production
This invention relates to providing gene fusions producing an optimal amount of polypeptide.
In a publication by Backman and Ptashne, Cell,
Vol. 13, pages 65-71(1978), there was described a method for producing unfused protein by creating, in front of the gene for the protein, a hybrid ribosome binding site consisting of a Shine
Dalgarno sequence (attached to a portable promoter), at least two other base pairs, and the
ATG (translation start site) of the gene for the protein, and then cloning the fused gene into a microorganism. The quantity of protein produced is in part a function of the length of the hybrid ribosome binding site; that is, the distance, in terms of base pairs, between the Shine-Dalgarno sequence and the translation start site. This distance is varied by varying the position of the portable promoter, as described in our earlier application, supra.
When the hybrid ribosome binding site is of some optimal length, protein production is maximized. One method of determining the promoter position which yields this optimal ribosome binding site is to use a standard RIA technique to measure protein production.
However, standard techniques are cumbersome for some polypeptides, and unavailable for others.
The limitation of standard protein assaying methods can also impede the determination of the efficacy of a naturally occurring ribosome binding site. Similarly, these limitations can make it difficult or impossible to detect a mutation, spontaneous or induced, which results in increased polypeptide production.
We have discovered a new method for determining the amount of eukaryotic or prokaryotic polypeptide produced by a microorganism containing a desired gene coding for the polypeptide ("polypeptide", as used herein, includes proteins and small polypeptides). The method involves fusing an amino terminal region of a sample of the desired gene, which region codes for a fragment of the eukaryotic or prokaryotic polypeptide, to a carboxy terminal gene region coding for a different, assayable, polypeptide fragment. The fused gene is cloned into a microorganism, where it encodes an assayable hybrid polypeptide product having an amino-terminal fragment of the desired polypeptide, and a carboxy-terminal fragment of the assayable polypeptide. The amount of assayable hybrid polypeptide is measured; this amount is directly proportional to the amount of eukaryotic or prokaryotic polypeptide.
The above principles and techniques are also used in another aspect of the invention, a method of providing, for a gene coding for a desired eukaryotic or prokaryotic polypeptide, a sample of the gene having one or more mutations causing the mutated gene to code for a greater amount of the desired polypeptide than non-mutated
samples of the gene. The method involves first providing samples of a fused gene including a carboxy-terminal gene region coding for an assayable polypeptide fragment fused to an amino-terminal gene region coding for a fragment of the desired polypeptide. The fused genes are cloned into microorganisms, where they produce assayable hybrid polypeptide.Any fused gene having one or more spontaneous mutations causing it to produce more of the hybrid polypeptide than non-mutated samples is selected, and then, from this fused gene, the gene for the desired polypeptide is reconstituted by any of the usual in vitro or in vivo methods. The gene is at this point ready to be cloned into a microorganism, where it can direct the production of higher levels of the desired polypeptide in pure form.
The above method can be modified by mutagenizing the microorganisms after the initial cloning step. This can be done using standard mutagens, e.g., X-rays or chemical mutagens such as nitrosoamines.
The mutation selecting method is particularly useful with regard to fusions which fail to produce iarge amounts of polypeptide no matter where the promoter is located. Successive mutations can eventually yield samples capable of efficient polypeptide production.
The above principles and techniques are also used in another aspect of the invention, a method for providing genes having maximally efficient hybrid ribosome binding sites. The method involves providing, as described above, samples of a fused gene including a gene region coding for a fragment of the desired eukaryotic or prokaryotic polypeptide fused to a gene region coding for a different, assayable, polypeptide fragment. The fused gene encodes an assayable hybrid polypeptide product having an amino-terminal fragment of the desired polypeptide, and a carboxy-terminal fragment of the assayable polypeptide. A portable promoter is placed at varying distances in front of this fused gene, and the fusions having the promoter in the position producing the most assayable hybrid polypeptide product are selected.The gene for the desired polypeptide is then reconstituted, and can produce high levels of unfused polypeptide.
In the drawings,
Fig. 1 shows a schematic diagram of a generalized fused gene of the invention,
Figs. 2 and 3 show diagrammatic representations of the construction of two fused genes of the invention,
Fig. 4 shows a diagrammatic representation of in vitro gene reconstitution, and
Fig. 5 shows a diagrammatic representation of in vivo gene reconstitution.
Any carboxy terminal gene region coding for an assayable polypeptide fragment can be used in accordance with any aspect of the invention, and the gene region coding for the desired polypeptide fragment can be inserted in the gene region for the different assayable polypeptide fragment in any position which does not destroy assayability.
To eliminate concern with whether or not the inserted desired polypeptide fragment will destroy assayability, prior to that insertion, a gene or gene region can be used to the gene region for the assayable polypeptide fragment to serve as the insertion site.
Referring to Fig. 1, a fused gene of the invention which facilitates gene insertion as described above includes from right to left, a first carboxy-terminal gene region coding for an assayable polypeptide fragment fused to a second amino-terminal gene region bearing a restriction site. (Herein, "left" and "right" are used to indicate positions which are transcribed, respectively, earlier and later). If that region does not naturally bear such a site, a DNA linker sensitive to one or more restriction enzymes is inserted in the region.
The natural restriction site or DNA linker serves as the site for the insertion into the second gene region of a third gene region, an amino-terminal region of a gene for a fragment of any desired prokaryotic or eukaryotic polypeptide. This region may have its own translation start site (ATG), or it may be lacking such a site. In the latter instance, such a site can be fused to the left end of the desired gene region.
In front of the third gene region is a promoter which includes a transcription start site and a
Shine-Dalgarno sequence. This promoter is either the native promoter or, in the method involving varying the promoter position, a portable promoter.
There are always at least two base pairs between the Shine-Dalgarno sequence and the translation start site. In the case of the assay method not employing a portable promoter, they are of course part of the native DNA strand which includes the desired gene. In the method involving varying promoter position, these base pairs are either originally attached to the promoter's Shine
Dalgarno sequence, or to be desired gene, or some can be attached to each.
If the base sequence of the gene region for the desired polypeptide fragment is known to the extent that the correct reading frame for that gene region is known, a DNA linker, if one is necessary, is positioned such that the desired gene region, after insertion, will be in phase with the first gene region. If the sequence is not adequately known, the desired gene region can be inserted into three different fusions, having differently positioned linkers. The linkers can be positioned anywhere on the second gene region, but only three positions are needed to cover all three possible reading frames. The linker position which allows translation of the particular gene region desired to proceed in frame into the first gene region is the one to be used with that gene region.
To provide the fused genes having the optimally-placed promoter, a portable promoter is attached to samples of the fusions described above at varying distances from the location of the translation start site. The samples of the fused genes, attached to promoters, are cloned into microorganisms. The fused genes bearing the promoter fragment at the optimal distance from the translation start site are recognized and selected on the basis of their production of the greatest amount of assayable hybrid polypeptide.
The gene for the desired eukaryotic or prokaryotic polypeptide, with the optimally placed promoter, is then reconstituted. Reconstitution can be carried out on the same fusion sample which was used for the polypeptide assay, or it can be performed on a sample of that fusion set aside before the polypeptide assay was carried out.
Also, because the optimal promoter distance is known after the polypeptide assay has been done, a portable promoter can be inserted the optimal distance from another sample of the fusion, and reconstitution can then be performed on that fusion. After reconstitution, the gene is ready to direct the production, in a microorganism, of a maximum amount of the desired polypeptide in pure form.
The following specific example is intended to illustrate more fully the nature of the present invention without acting as a limitation upon its scope.
EXAMPLE Three plasmids, pLG 200, pLG 300, and pLG 400 were constructed. Each has a site, vulnerable to a restriction enzyme, in a different translational reading frame on a region of the lacl gene. Each of the three plasmids also contains a region of the IacZ gene which codes for an assayable fragment of the polypeptide ,B- galactosidase. Plasmids pLG 300 and pLG 400 were constructed from pLG 200, which was in turn constructed in the following manner, as shown in Fig. 2.
First, plasmid pLG 2, containing an intact lacllacP-lacZ gene fusion, was constructed as follows
An Eco RI fragment from pMC4 containing the intact lacl gene, the lac promoter, and the amino terminal region of lacZ was ligated to an Eco RI blunt ended fragment (from A112, described in
Ptashne in The Operon, Miller et al., eds. (Cold
Spring Harbor Laboratory, New York 1978)) containing the carboxy terminal region of JacZ to create a fragment with an intact lacl-lacP-lacZ region. This fragment was inserted into a backbone containing pBR 322 DNA from the RI site to the Pvull site, yielding plasmid pLG 2.
Next, a lacl-lacZfused gene was crossed onto pLG 2 by in vivo recombination to yield plasmid pLG 5. This plasmid was then partially digested with Pvull, and the amino terminal region of the lacl region was replaced with a Hin d III linker to yield pLG 200 which, when opened at the Hin d Ill site, provides for one of the three possible translational reading frames.
Plasmid pLG 300, capable of providing a second reading frame, was constructed from pGL 200 as follows. pLG 200 was cut with
Hin d III, the ends were filled in the DNA polymerase, and a Bam linker inserted, yielding pLG 300.
To provide the third reading frame, pLG 300 was cut with Bam, filled in, and Hin d Ill linker was inserted to yield pLG 400.
Referring to Fig. 3, a region of a gene for a desired polypeptide, rabbit /3-globin, was inserted into plasmid pLG 300 by ligating a filled-in Pst
Bam globin fragment from pGL 6 to a filled-in Pst
Bam backbone fragment of pLG 300 to yield pLG 302.
A lac promoter fragment was inserted varying distances in front of the translation start site of the fused gene, according to the method described in
Ptashne et al. Serial No. 3,102, supra. pLG 302 was opened with Hin d Ill, resected with exonuclease Ill and S1 (or Bal 131), and then cut with Pst so that a promoter fragment with a Pst end and a blunt end could be inserted.
Plasmids with promoters at varying distances from the start of the fused gene were cloned into
E. coli and grown on indicator agar which changes color to a degree depending on the level of p-galactosidase produced by the bacteria. Those colonies producing the greatest color change were selected as the ones having the promoter optimally positioned.
Referring to Fig. 4, the intact !;-globin gene was reconstituted in vitro as follows. From the selected plasmids, a Rl-Sau 3A fragment containing the lac promoter and the amino terminal coding portion of the ,-globin gene was prepared. This fragment was ligated to a Bam-Alu fragment from p/3G1 (Efstratiadis et al. (1977) Cell, 10, 571-585) containing the carboxy terminalcoding region of the 83-globin gene. The reconstituted gene was then inserted into an Ri--Pvulli backbone of pBR 322. This reconstituted gene, when cloned into E. coli, which was then cultured, directed the production
of maximal quantities of the desired rabbit ,B-globin.
Referring to Fig. 5, in another sample, the ss-globin gene could be reconstituted in vivo as follows. The fusion bearing the optimally-placed promoter was inserted into a plasmid having a marker for ampicillin resistance. This plasmid was then crossed with another plasmid carrying the missing portion of the gene for /3-globin, plus a small region of overlap to provide homology for genetic recombination. The latter plasmid bore no lac promoter, but it did carry a marker for tetracycline resistance. The desired recombination separated the lac promoter from the i3- galactosidase gene; this recombination was thus identifiable among other recombinants exhibiting both drug resistances by its lac-phenotype.
The reconstitution method described herein are the same ones to be used after employing the method of the invention to select desirable mutants which have arisen spontaneously or which have been induced by means of a mutagen.
Other embodiments are within the following claims. For example, the gene region for an assayable polypeptide can be fused to genes other than lacl; an example is the t antigen of Simian virus, discussed in Robert et al. (1979), Proc. Natl.
Acad. Sci., U.S.A., 76, 5596-5600. Other suitable genes, e.g. Male and lamB are described in Bassford et al., in The Operon, Miller et al., eds., pp. 245-261 (Cold Spring Harbor Laboratory,
New York 1978). Also, among the genes for polypeptides having assayability in the carboxyterminal region which can be used in place of the 5-galactosidase gene are, for example, the E. coli
trpC and trpD genes, which code for two polypeptides, each having two specific enzymatic activities in tryptophane biosynthesis; and yeast genes which code for enzymatically-active polypeptides. For example, one such yeast gene codes for a polypeptide having three enzymatic activities involved in histidine biosynthesis.
Claims (13)
1. A fused gene comprising:
a first, carboxy terminal gene region coding for an assayable polypeptide fragment,
a second, amino terminal gene region fused to said carboxy terminal gene region, said amino terminal gene region having a restriction site,
a third, amino terminal gene region coding for a fragment of a eukaryotic or prokaryotic polypeptide, said third gene region being located at said restriction site and, in front of said third gene region,
a translation start site and a portable promoter having a transcription state site.
2. The fused gene of claim 1, wherein
said first gene region is a region of the gene coding for co/i cold j3-galactosidase, and said second gene region is a region of the gene coding for E. coli repressor.
3. A method of determining the amount of a eukaryotic or prokaryotic polypeptide produced by a microorganism containing a desired gene coding for said polypeptide, which method comprises
fusing an amino terminal region of a sample of said desired gene to a carboxy terminal gene region coding for a different, assayable polypeptide fragment thereby to produce a fused gene coding for an assayable hybrid polypeptide,
cloning said fused gene into a microorganism, and
measuring the amount of said assayable hybrid polypeptide produced by said fused gene in said microorganism, said amount being directly proportional to the amount of said eukaryotic or prokaryotic protein.
4. A method of providing, for a fused gene coding for a desired eukaryotic or prokaryotic polypeptide, a sample of said fused gene having its portable promoter located an optimal distance from its translation start site comprising the steps of
providing samples of a fused gene comprising a carboxy terminal gene region coding for an assayable polypeptide fragment fused to an amino terminal gene region coding for a fragment of said desired eukaryotic or prokaryotic polypeptide, said fused gene being capable of coding for an assayable hybrid polypeptide,
inserting said portable promoter at varying distances in front of the translation state site of said samples of said fused gene,
cloning said samples of said fused gene into microorganisms,
assaying said assayable hybrid polypeptide produced by said fused genes in said microorganisms,
selecting said fused gene producing the greatest amount of said assayabie hybrid polypeptide, and
reconstituting, from said selected fused gene, the gene coding for said desired eukaryotic or prokaryotic polypeptide.
5. A method of providing, for a gene coding for a desired eukaryotic or prokaryotic polypeptide, a sample of said gene having one or more mutations causing said mutated gene to code for a greater amount of said desired polypeptide compared to non-mutated samples of said gene, comprising the steps of
providing samples of a fused gene comprising a carboxy terminal gene region coding for an assayable polypeptide fragment fused to an amino terminal gene region coding for a fragment of said desired eukaryotic or prokaryotic polypeptide, said fused gene being capable of coding for an assayable hybrid polypeptide,
cloning said samples of said fused gene into microorganisms,
assaying said assayable hybrid polypeptide produced by said fused genes in said microorganisms,
selecting the mutated fused gene producing a greater amount, compared to non-mutated
samples of said fused gene, of said assayable
hybrid polypeptide, and
reconstituting, from said selected fused gene, the gene coding for said desired eukaryotic or prokaryotic polypeptide.
6. The method of claim 5, further comprising, following said step of cloning said fused gene into said microorganisms, the step of mutagenizing said microorganisms.
7. The method of claim 4, wherein said gene region coding for said assayable polypeptide fragment is a region of the E. coli gene coding for /3-galactosidase.
8. The method of claim 5 or 6, wherein said gene region coding for said assayable polypeptide fragment is a region of the E. colt gene coding for ,8-galactosidase.
9. A fused gene substantially as hereinbefore described in the Example.
10. A method of determining the amount of eukaryotic or prokaryotic polypeptide produced by a microorganisms substantially as hereinbefore described in the Example.
11. A method of preparing a fused gene substantially as hereinbefore described in the
Example.
1 2. A method of preparing a gene housing one or more mutations substantially as hereinbefore described in the Example.
13. Polypeptide or protein produced by an organism housing a fused gene as claimed in claim 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13115280A | 1980-03-17 | 1980-03-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB2071671A true GB2071671A (en) | 1981-09-23 |
| GB2071671B GB2071671B (en) | 1983-10-05 |
Family
ID=22448125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8108136A Expired GB2071671B (en) | 1980-03-17 | 1981-03-16 | Polypeptide production |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JPS56167698A (en) |
| AT (1) | AT378004B (en) |
| BE (1) | BE887991A (en) |
| CA (1) | CA1198385A (en) |
| DE (2) | DE3110031A1 (en) |
| ES (2) | ES8205432A1 (en) |
| FR (1) | FR2478125B1 (en) |
| GB (1) | GB2071671B (en) |
| IT (1) | IT1144705B (en) |
| NL (1) | NL8101289A (en) |
| SE (1) | SE8101665L (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2511033A1 (en) * | 1981-08-10 | 1983-02-11 | Genex Corp | EXPRESSION VECTORS FOR INTRODUCING A GENE INTO A PROCARYOTE ORGANISM |
| WO1983004262A1 (en) * | 1982-05-25 | 1983-12-08 | Brandeis University | Method of producing protein fragments |
| GB2133408A (en) * | 1980-12-31 | 1984-07-25 | Ilkka Palva | Method for improving the production of proteins in bacillus |
| US4532207A (en) * | 1982-03-19 | 1985-07-30 | G. D. Searle & Co. | Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase |
| WO1985003522A1 (en) * | 1984-02-08 | 1985-08-15 | Cetus Corporation | Monitoring and control systems for recombinant manipulations |
| WO1986006635A1 (en) * | 1985-05-15 | 1986-11-20 | Biotechnology Australia Pty. Ltd. | Oral vaccines |
| US4849351A (en) * | 1982-08-27 | 1989-07-18 | Gakuzo Tamura | Multiple reading frame Escherichia coli expression vectors |
| US4859609A (en) * | 1986-04-30 | 1989-08-22 | Genentech, Inc. | Novel receptors for efficient determination of ligands and their antagonists or agonists |
| US4923808A (en) * | 1985-03-12 | 1990-05-08 | Genentech, Inc. | Method for identifying mutants secreting high levels of heterologous proteins |
| US5030576A (en) * | 1986-04-30 | 1991-07-09 | Genentech, Inc. | Receptors for efficient determination of ligands and their antagonists or agonists |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4874702A (en) * | 1980-09-08 | 1989-10-17 | Biogen, Inc. | Vectors and methods for making such vectors and for expressive cloned genes |
| US4582800A (en) * | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| EP0130074B1 (en) * | 1983-06-27 | 1991-02-06 | Genentech, Inc. | Portable inducible control system, expression vectors containing them, microorganisms transformed with them, and their use in expressing exogenous protein |
| JP6297223B2 (en) | 2015-06-23 | 2018-03-20 | 富士フイルム株式会社 | Electroacoustic transducer film and electroacoustic transducer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL55890A (en) * | 1977-11-08 | 1984-01-31 | Genentech Inc | Method and means for polypeptide production involving expression of a heterologous gene,and as products therefrom recombinant microbial cloning vehicles containing said gene |
| FI792481A (en) * | 1978-08-11 | 1980-02-12 | Univ California | SYNTHESIS OF ENCAROYTIC PROTEIN GENOM ANVAENDNING AV MICRO-ORGANISM |
| NL8000127A (en) * | 1979-01-15 | 1980-07-17 | Harvard College | METHOD FOR FORMING PROKARYOTIC OR EUKARYOTIC PROTEINS AND A GENERALLY COUPLED GENE. |
-
1981
- 1981-03-16 GB GB8108136A patent/GB2071671B/en not_active Expired
- 1981-03-16 ES ES500397A patent/ES8205432A1/en not_active Expired
- 1981-03-16 IT IT67359/81A patent/IT1144705B/en active
- 1981-03-16 DE DE19813110031 patent/DE3110031A1/en not_active Withdrawn
- 1981-03-16 DE DE19813153267 patent/DE3153267A1/de active Pending
- 1981-03-16 SE SE8101665A patent/SE8101665L/en not_active Application Discontinuation
- 1981-03-16 CA CA000373031A patent/CA1198385A/en not_active Expired
- 1981-03-17 FR FR8105347A patent/FR2478125B1/en not_active Expired
- 1981-03-17 JP JP3733881A patent/JPS56167698A/en active Pending
- 1981-03-17 BE BE0/204159A patent/BE887991A/en not_active IP Right Cessation
- 1981-03-17 AT AT0122281A patent/AT378004B/en not_active IP Right Cessation
- 1981-03-17 NL NL8101289A patent/NL8101289A/en not_active Application Discontinuation
-
1982
- 1982-03-01 ES ES510007A patent/ES8306177A1/en not_active Expired
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2133408A (en) * | 1980-12-31 | 1984-07-25 | Ilkka Palva | Method for improving the production of proteins in bacillus |
| US5010000A (en) * | 1980-12-31 | 1991-04-23 | Genesit Oy | Method for the preparation of a selected protein or a part thereof in Bacillus strain bacteria |
| US5010015A (en) * | 1980-12-31 | 1991-04-23 | Genesit Oy | Recombinant DNA-molecules and method for protein production |
| FR2511033A1 (en) * | 1981-08-10 | 1983-02-11 | Genex Corp | EXPRESSION VECTORS FOR INTRODUCING A GENE INTO A PROCARYOTE ORGANISM |
| US4532207A (en) * | 1982-03-19 | 1985-07-30 | G. D. Searle & Co. | Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase |
| WO1983004262A1 (en) * | 1982-05-25 | 1983-12-08 | Brandeis University | Method of producing protein fragments |
| US4849351A (en) * | 1982-08-27 | 1989-07-18 | Gakuzo Tamura | Multiple reading frame Escherichia coli expression vectors |
| WO1985003522A1 (en) * | 1984-02-08 | 1985-08-15 | Cetus Corporation | Monitoring and control systems for recombinant manipulations |
| US4923808A (en) * | 1985-03-12 | 1990-05-08 | Genentech, Inc. | Method for identifying mutants secreting high levels of heterologous proteins |
| WO1986006635A1 (en) * | 1985-05-15 | 1986-11-20 | Biotechnology Australia Pty. Ltd. | Oral vaccines |
| US4859609A (en) * | 1986-04-30 | 1989-08-22 | Genentech, Inc. | Novel receptors for efficient determination of ligands and their antagonists or agonists |
| US5030576A (en) * | 1986-04-30 | 1991-07-09 | Genentech, Inc. | Receptors for efficient determination of ligands and their antagonists or agonists |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1144705B (en) | 1986-10-29 |
| DE3153267A1 (en) | 1985-08-14 |
| FR2478125B1 (en) | 1985-07-05 |
| CA1198385A (en) | 1985-12-24 |
| ES500397A0 (en) | 1982-06-01 |
| NL8101289A (en) | 1981-10-16 |
| IT8167359A0 (en) | 1981-03-16 |
| GB2071671B (en) | 1983-10-05 |
| ATA122281A (en) | 1984-10-15 |
| FR2478125A1 (en) | 1981-09-18 |
| JPS56167698A (en) | 1981-12-23 |
| ES510007A0 (en) | 1983-05-01 |
| ES8205432A1 (en) | 1982-06-01 |
| SE8101665L (en) | 1981-09-18 |
| BE887991A (en) | 1981-07-16 |
| AT378004B (en) | 1985-06-10 |
| DE3110031A1 (en) | 1982-01-07 |
| ES8306177A1 (en) | 1983-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gardel et al. | secD, a new gene involved in protein export in Escherichia coli | |
| US4952501A (en) | Method for analyzing and synthesizing functional polypeptide sequences for assembly into enhanced or multi-functional proteins | |
| Close et al. | Construction and characterization of the chloramphenicol-resistance gene cartridge: a new approach to the transcriptional mapping of extrachromosomal elements | |
| Shultz et al. | A previously unidentified gene in the spc operon of Escherichia coli K12 specifies a component of the protein export machinery | |
| CA1198385A (en) | Optimal polypeptide production | |
| Calamia et al. | lac permease of Escherichia coli: topology and sequence elements promoting membrane insertion. | |
| EP0035384B1 (en) | Deoxynucleotide linkers to be attached to a cloned dna coding sequence | |
| EP0199801B1 (en) | Methods for protein binding enzyme complementation assays | |
| US4914025A (en) | Export of intra-cellular substances | |
| Schümperli et al. | Efficient expression of Escherichia coli galactokinase gene in mammalian cells. | |
| Ghosal et al. | DNA Sequence of the mini-insertion IS 2–6 and its relation to the sequence of IS 2 | |
| US4769327A (en) | Secretion vector | |
| Linder et al. | An essential replication gene, repA, of plasmid pSC101 is autoregulated | |
| Menon et al. | Activation of ara operons by a truncated AraC protein does not require inducer. | |
| US20030138843A1 (en) | Method for determining and modifying protein/peptide solubility | |
| KR100566702B1 (en) | Positive-negative selection for homologous recombination | |
| Hart et al. | Deletion analysis of the lambda tR1 termination region: effect of sequences near the transcript release sites, and the minimum length of rho-dependent transcripts | |
| WO2000026366A1 (en) | Isolated nucleic acids encoding a secretory signal for expression and secretion of heterologous recombinant proteins | |
| JPH07250689A (en) | Periplasm membrane connective system for detecting protein-protein interaction | |
| Sprengel et al. | Translationally coupled initiation of protein synthesis in Bacillus subtilis | |
| Thomas et al. | Escherichia coli plasmid vectors containing synthetic translational initiation sequences and ribosome binding sites fused with the lacZ gene | |
| Lindbladh et al. | The design of a simple competitive ELISA using human proinsulin-alkaline phosphatase conjugates prepared by gene fusion | |
| Adhin et al. | Translational regulation of the lysis gene in RNA bacteriophage fr requires a UUG initiation codon | |
| Davison et al. | Bacteriophage T7 RNA polymerase-controlled specific gene expression in Pseudomonas | |
| EP0419081A2 (en) | Method for protein binding enzyme complementation assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |